EUCODIS Bioscience, a developer and manufacturer of customized enzymes today announced that it has launched a high-performance beta-lactamase designed to inactivate a broad range of beta-lactam antibiotics. EUCODIS Bioscience is marketing the product under the LacBuster(TM) brand.
Beta-lactamases are enzymes that inactivate beta-lactam antibiotics, hydrolyzing the beta-lactam ring, a molecular structure common to these drugs. This property makes beta lactamases an important tool in the manufacture of beta-lactam antibiotics, where they are used for sterility testing of bulk products. Within the USD 25 billion antibiotics market, beta-lactam antibiotics are the most widely prescribed group of drugs. Beta-lactamase enzymes are also used by the diagnostics industry, and in other areas.
"Our LacBuster(TM) beta-lactamase addresses the needs of leading antibiotics manufacturers, as it inactivates all relevant beta-lactam antibiotics, including penicillins, cephalosporins up to the 5th generation, and carbapenems, and shows an activity significantly higher than that of other products currently in the market", said Bhupinder Hundle, Senior Vice President Marketing & Sales, EUCODIS Bioscience.
"The launch of a product that provides a better performance than previously available in the market demonstrates that we are deeply committed to helping pharmaceutical manufacturers and drug developers keeping their competitive edge", said Thomas Fischer, CEO EUCODIS Bioscience. "At the same time, demand from the broader chemical industry is gaining momentum. With our enzyme products as well as our custom-engineering and manufacturing services we have been making strong inroads in areas such as specialty chemicals, cosmetics, animal feeds, as well as high-value products from biomass."
Diabetes drugs may reduce risk of opioid overdose and alcohol intoxication